Overview

A Study to Evaluate the Efficacy and Safety of ALN-HSD in Adult Participants With Non-alcoholic Steatohepatitis (NASH) With Fibrosis With Genetic Risk Factors

Status:
Not yet recruiting
Trial end date:
2026-08-17
Target enrollment:
Participant gender:
Summary
The primary objective of Study 1 and Study 2 is to evaluate the effect of ALN-HSD on histopathologic assessment of liver fibrosis. The secondary objectives of Study 1 and Study 2 are: - To evaluate the effect of ALN-HSD on histopathologic assessment of steatohepatitis - To evaluate the effect of ALN-HSD on serum biomarkers of hepatocellular injury - To evaluate the effect of ALN-HSD on serum biomarkers of fibrosis - To evaluate the effect of ALN-HSD on HSD17B13 expression - To evaluate the effect of ALN-HSD on hepatocellular apoptosis - To evaluate the effect of ALN-HSD on slowing progression of liver disease - To evaluate safety and tolerability of ALN-HSD
Phase:
Phase 2
Details
Lead Sponsor:
Regeneron Pharmaceuticals